This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.
Dashboard: Filter Bricks
Main page content
The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.
This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
Summarizes key findings from the 2015 National Survey on Drug Use and Health (NSDUH) for indicators of substance use and mental health among people aged 12 years old or older in the civilian, non-institutionalized population of the United States.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This NSDUH report discusses trends in the prevalence of mental illness, substance use disorders, or both among adolescents and adults in the United States.
This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
Displaying 1 - 10 out of 15